Loading tape…Loading tape…
AbbVie Inc.
ABBV
ABBV
A report from fool.com compares AbbVie and Pfizer in a feature titled 'AbbVie vs. Pfizer: Which Healthcare Stock Is a Better Buy in 2026?'. AbbVie currently carries a market capitalization of $452,899,671,735, supported by full-year revenue of $61,160,000,000 and a TTM EPS of 3.565233496255206. These operational metrics correspond to a PE ratio of 72.21862234117481 and a free cash flow yield of 4.3457748433777414%.
Based on fool.comForget High-Yield Traps: AbbVie Is the Dividend King to Buy and Hold Through Any Rate Cycle
If a Stock Market Crash Is Coming, History Says These 3 ETFs Are the Smartest Buys
SKYRIZI® (risankizumab) and RINVOQ® (upadacitinib) Data Highlight Long-Term Clinical and Endoscopic Outcomes Across Inflammatory Bowel Disease (IBD) at UEGW 2026
SKYRIZI® (risankizumab) and RINVOQ® (upadacitinib) Data Highlight Long-Term Clinical and Endoscopic Outcomes Across Inflammatory Bowel Disease (IBD) at UEGW 2026
Here's How Many Shares of AbbVie You'd Need for $5,000 in Yearly Dividends
AbbVie vs. Pfizer: Which Healthcare Stock Is a Better Buy in 2026?
Revenue & Net Income (5Y)
EPS & Growth (5Y)
Free Cash Flow (5Y)
Capital Returns
Operating & Net Margin (5Y)
CapEx vs. Free Cash Flow (5Y)
Capital Allocation (5Y)
R&D and SG&A Intensity (5Y)
EBITDA (5Y)
Cost of Revenue (5Y)
Market Cap (5Y)
Ask Blinx with professional market data, charts beside chat, and your portfolio context.
Default quotes are Lang & Schwarz. NASDAQ is the delayed listing price. Charts stay daily. Not investment advice.